Intra-IMMUSG

Intra-IMMUSG, based in Singapore, Singapore, is a biotechnology company. Intra-ImmuSG is a Phase 2 clinical-stage biotechnology company developing antibody-based cancer immunotherapies that target intracellular tumour antigens exposed on the cancer cell surface. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3). The largest, NCT07541001 (PRL3-Zumab in Patients With Advanced Solid Tumours), plans to enrol 60 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.